- John C. Malone Professor of Molecular, Cellular, and Developmental Biology, Departments of Chemistry and Pharmacology, Yale School of Medicine, Yale University
- Professor (Chemistry, Pharmacology, Management), Departments of Chemistry and Pharmacology, Yale School of Medicine, Yale University
- Executive Director, Yale Center for Molecular Discovery, Yale School of Medicine, Yale University
Dr. Craig Crews is the American Cancer Society Professor of Molecular, Cellular, and Developmental Biology at Yale University, with joint appointments in the Departments of Chemistry and Pharmacology. His research focuses on chemical biology, particularly controlled proteostasis and targeted protein degradation.
Dr. Crews is a pioneer in the field of targeted protein degradation. His laboratory’s research contributed to the development of the anti-cancer drug carfilzomib (Kyprolis), and he is credited with developing PROTACs (proteolysis-targeting chimeras), a transformative therapeutic modality. He founded Arvinas in 2013, which developed the first PROTAC therapy for breast cancer — approved by the FDA in May 2026.
Dr. Crews has been recognized with numerous prestigious honors, including the 2025 Passano Award, the 2024 Kimberly Prize from Northwestern University, the 2023 Gabbay Prize from Brandeis University, the 2021 Scheele Award of the Swedish Pharmaceutical Society, the 2020 Heinrich Wieland Prize from the Boehringer Ingelheim Foundation, and the 2018 Royal Society of Chemistry Khorana Prize.